| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910624320403321 |
|
|
Titolo |
Radiopharmaceuticals in the management of leptomeningeal metastasis / / Franklin C. L. Wong, editor |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham, Switzerland : , : Springer, , [2022] |
|
©2022 |
|
|
|
|
|
|
|
|
|
ISBN |
|
9783031142918 |
9783031142901 |
|
|
|
|
|
|
|
|
Descrizione fisica |
|
1 online resource (236 pages) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di bibliografia |
|
Includes bibliographical references and index. |
|
|
|
|
|
|
Nota di contenuto |
|
Intro -- Preface -- Acknowledgments -- Contents -- Contributors -- Chapter 1: Human Leptomeningeal Metastasis (LM): Epidemiology and Challenges -- Leptomeningeal Metastasis Frequency of Occurrence/Incidence -- Challenges of LM Treatment -- Limited Knowledge of Meningeal Anatomy, Physiology, and Pathophysiology -- Limited LM Diagnosis: Cytology, MRI Abnormalities, PET-CT, RANO-LM -- Limited Efficacy of LM Therapy -- Advantages of Radiopharmaceuticals for Intrathecal Diagnostics and Therapeutics -- References -- Chapter 2: State of Art of LM Radiographic Diagnosis: Anatomic and Functional Imaging -- Introduction -- Diagnosis -- MR Imaging -- CSF Flow Studies -- PET/CT -- Response Assessment in Neuro-Oncology (RANO) Proposal for Response Criteria -- References -- Chapter 3: Radionuclides in the Diagnosis and Therapy in Neuro-Oncology -- Introduction -- Conventional Nuclear Medicine Studies -- SPECT and PET Radiopharmaceuticals in Neuro-Oncology -- SPECT Radiopharmaceuticals -- PET Radiopharmaceuticals -- Glucose Metabolism PET Tracers: FDG -- Amino Acid PET Tracers -- PET Tracers for Assessment of Tumor Hypoxia -- PET Tracers for Assessment of Cellular Proliferation -- PET Tracers for Assessment of Tumor Perfusion -- PET Tracers for Assessment of Tumor Angiogenesis -- PET Imaging for Theranostics in Neuro-Oncology -- Newer or Potential Tracers for Emerging Cell Targets in Neuro-Oncology PET -- |
|
|
|
|
|
|
|
|
|
Radionuclide Therapy -- Introduction -- Neurokinin Type-1 Receptor -- Tenascin C -- Fibronectin -- Epidermal Growth Factor Receptor -- DNA-Histone H1 Complex -- Somatostatin Receptors -- Prostate Membrane Antigen -- Amino Acid Metabolism -- Matrix Metalloproteinase -- Radiopharmaceuticals Used in Preclinical Studies -- Conclusions -- References -- Chapter 4: Scintigraphy of Human CSF Flow in Patients with Leptomeningeal Metastasis. |
Introduction: Imaging of Human CSF Flow -- Intrathecal Radiopharmaceuticals Used in Humans (Table 4.1) -- Imaging: Multiple Planar Scans of Multiple Time Points -- CSF Flow Abnormalities in LM -- Intrathecal In-111 DTPA and Pharmacokinetics in LM -- Whole-Body Scan Can Derive Effective Half-Life (Te) in CSF -- Clearance of Tracer in Human CSF Space (Fig. 4.2a, b) -- CSF Clearance of In-111 DTPA in LM (Figs. 4.3 and 4.4) -- Slow CSF Clearance with CSF Blockage (Fig. 4.5a, b) -- Fast CSF Clearance with CSF Leakage (Fig. 4.6) -- Whole-Body CSF Imaging with Tc99m DTPA (Figs. 4.5b and 4.7) -- Whole-Body Ga-67 Scan Showed CSF Patency (Fig. 4.8) -- Intraparenchymal Injection (Fig. 4.9a-c) -- Malfunction of Ommaya Reservoir (Fig. 4.10a, b) -- Ventriculoperitoneal Shunt (Figs. 4.11a-c and 4.12) -- SPECT-CT of Cisternograms -- Discussion -- Intrathecal Radiopharmaceuticals -- Effective Half-Life (Te) of Radiopharmaceuticals in CSF -- Whole-Body Scans and Radiation Dosimetry -- References -- Chapter 5: State of Art of LM Therapies: Intrathecal and Systemic Approaches -- Introduction -- Intrathecal (IT) Chemotherapy -- Route of Administration of IT Chemotherapy -- Commonly Used IT Chemotherapies -- Experimental IT Treatments for LM -- Temozolomide -- Topotecan -- Mafosfamide -- Diaziquone -- ACNU -- Immunotherapy -- Immunotoxins -- Checkpoint Inhibitors -- Radiolabeled Monoclonal Antibodies -- IT Immunotherapy -- Gene Therapy -- Systemic Chemotherapy -- Hormonal Therapy -- Targeted Therapies -- Breast Cancer -- IT Trastuzumab -- Lung Cancer -- Melanoma -- Conclusion -- References -- Chapter 6: Radiation Therapy for Leptomeningeal Disease -- Introduction -- Indications for Radiotherapy -- Good Risk LMD -- Poor Risk LMD -- Radiotherapy Details and Techniques -- Involved-Field Radiotherapy -- Whole Brain Radiotherapy -- Craniospinal Irradiation. |
Special Histologic Considerations -- Mixed Histologies -- Breast Cancer -- Pediatric Central Nervous System Disease -- Gastrointestinal Cancer -- Adult CNS Gliomas -- Non-small Cell Lung Cancer -- Melanoma -- Leukemia/Lymphoma -- Gynecologic Cancer -- Esthesioneuroblastoma -- Pediatric Rhabdomyosarcoma -- Treatment Related Toxicities -- Involved-Field Radiation Therapy -- Whole Brain Radiation Therapy -- Craniospinal Irradiation -- Conclusions -- References -- Chapter 7: Neurophysiology Evaluation in Leptomengeal Metastasis Disease -- Introduction -- Evoked Potentials (SSEP, BAER, VEP, TMS) -- References -- Chapter 8: Radionuclide Leptomeningeal Metastasis Therapy Trials -- Introduction: Rationale for Intrathecal Radionuclide Therapy Trials (Table 8.1) -- P-32 Chromic Phosphate Colloids -- Au-198 Gold Colloids -- I-125 Iododeoxyuridine (IUDR) -- Radiolabeled Monoclonal Antibodies -- I-131 MoAb (HMGF1, HMFG2, UJ181.4, F811.13, FD32) -- I-131 Mel 14 F (ab′)2 -- I-131 81C6 -- I-124 and I-131 3F8 -- I-124 and I-131 Omburtamab -- Lu-177 DTPA-Omburtamab -- Intrathecal Radionuclide Therapy Dosing Scheme (Table 8.2) -- Efficacy and Toxicity of Intrathecal Radionuclide Therapy (Table 8.3) -- Radiation Dosimetry as Potential Guidance (Table 8.4) -- Conclusions -- References -- Chapter 9: Simulated Radiation Dosimetry Models After Intraventricular and Intralumbar Injection of Radiopharmaceuticals -- Introduction -- Methodology -- |
|
|
|
|
|
|
|
|
Radionuclides and Radiopharmaceuticals -- Biokinetic Models of CSF and Flow -- Radiation Dosimetry from Activity Absorbed into the Systemic Circulation -- MCNP Monte Carlo Radiation Transport Simulations -- Final Dosimetry Estimates -- Results from Intraventricular Injections [19] -- CSF and Organ Dosimetry -- Absorbed Dose as a Function of Depth Surrounding CSF Spaces -- Ventricular Stasis (VS) -- Results from Intralumbar Injections. |
CSF and Organ Dosimetry -- Absorbed Dose Vs. Depth -- Lumbar Stasis (LS) -- Conclusion -- Discussion -- Limitations of Dosimetric Models -- Prediction of Potential Toxicities and Efficacy in LM -- Dosing Considerations: An Example with Y-90 DTPA -- Additional Dosimetric Considerations: CSF Blockage, Postsurgical Cavity Therapy -- Appendix: Dosimetry Methods for Brain Dose as a Function of Depth -- References -- Chapter 10: Human Radiation Dosimetry from Imaging: Guidance for Therapy -- Introduction -- Radionuclide and Radiopharmaceutical Properties -- Quantitative Imaging of Radionuclides -- Data Processing for Dosimetry -- Summary -- References -- Chapter 11: Regulatory Oversight of Radiopharmaceuticals -- Introduction -- Federal Regulatory Authority of Radiopharmacuticals -- Nuclear Regulatory Commission -- Food and Drug Administration -- Other Pertinent Regulatory Agencies -- Occupational Safety and Health Administration (OSHA) -- Environmental Protection Agency (EPA) -- Department of Transportation (DOT) -- State Regulatory Control -- NRC/State Health Radiation Control: RAM Inspection -- State Boards of Pharmacy (BOP): Pharmacy Inspection -- Accreditation Organizations: The Joint Commission Inspection -- Internal/Local Regulatory Authority -- Radiation Safety Committee/Radiation Safety Office -- Radioactive Drug Research Committee -- Institutional Review Board -- Regulatory Outlook of Radiopharmaceuticals -- References -- Chapter 12: Radionuclides in the Management of Leptomeningeal Metastasis: Framework and Opportunities -- Introduction: Radiopharmaceuticals in LM Management -- Intrathecal Radiopharmaceuticals for Assessment of CSF Flow -- CSF Radionuclide Imaging and Radiation Dosimetry -- Considerations in Intrathecal Radiopharmaceuticals Therapy -- Molecular Targeting Versus Geographic Targeting. |
Novel Intrathecal Use of Radiopharmaceuticals with Therapeutic Potentials -- Radioactive Cations -- Radioactive Anions (Halides- I-131, I-124 NaI, and Perhaps At-211) -- Radiolabeled Monoclonal Antibodies and Proteins -- Radio-Labeled Peptides (In-111 Octreotide, Cu-67 Sartate, Lu-177 Lutathera) -- Potential Use of Alpha Emitters (Radium-223) -- Conclusion -- References -- Index. |
|
|
|
|
|
| |